Natus Medical Incorporated (NASDAQ:NTUS) was the recipient of a large drop in short interest during the month of September. As of September 30th, there was short interest totalling 1,100,000 shares, a drop of 6.0% from the August 30th total of 1,170,000 shares. Currently, 3.3% of the company’s stock are sold short. Based on an average daily trading volume, of 186,400 shares, the short-interest ratio is currently 5.9 days.
Several equities research analysts have commented on NTUS shares. TheStreet upgraded shares of Natus Medical from a “d+” rating to a “c-” rating in a research note on Monday, September 30th. Zacks Investment Research lowered shares of Natus Medical from a “buy” rating to a “hold” rating in a research note on Friday, August 9th.
NASDAQ:NTUS traded up $1.36 on Thursday, hitting $32.38. The stock had a trading volume of 6,907 shares, compared to its average volume of 140,424. The company has a current ratio of 1.93, a quick ratio of 1.36 and a debt-to-equity ratio of 0.15. The firm has a market cap of $1.04 billion, a PE ratio of 22.77 and a beta of 0.73. Natus Medical has a 1 year low of $22.25 and a 1 year high of $35.73. The firm’s fifty day simple moving average is $30.20.
Natus Medical (NASDAQ:NTUS) last posted its quarterly earnings data on Thursday, July 25th. The company reported $0.34 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $0.30 by $0.04. The firm had revenue of $125.54 million during the quarter, compared to analyst estimates of $122.85 million. Natus Medical had a negative net margin of 7.38% and a positive return on equity of 10.73%. Research analysts expect that Natus Medical will post 1.27 EPS for the current fiscal year.
About Natus Medical
Natus Medical Incorporated provides neurology, newborn care, and hearing and balance assessment healthcare products and services worldwide. It offers products and services used for the screening, diagnosis, detection, treatment, monitoring, and tracking of common medical ailments in newborn care, hearing impairment, neurological dysfunction and neurosurgical treatments, epilepsy, sleep disorders, neuromuscular diseases, and balance and mobility disorders.
Featured Story: Rule of 72
Receive News & Ratings for Natus Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Natus Medical and related companies with MarketBeat.com's FREE daily email newsletter.